Uveitis Clinical Trials Study

MEERKAT – Uveitic Macular Edema 

We are collaborating with Genentech in a new randomized trial testing the efficacy and safety of intravitreal “RO7200220”, an IL6 inhibitor in patients with uveitic macular edema. We are excited to begin recruitment this month, as non-steroid treatment may be a paradigm shift in management. This maybe very beneficial to patients with steroid response or glaucoma.


Acelyrin – A Phase 2b Pivotal Study to Evaluate the Efficacy and Safety of Izokibep in Subjects with Non-infectious, Intermediate-, Posterior- or Pan-uveitis

Dr. Sapna Gangaputra, is participating in a research study to find out how safe and how well the study drug, Izokibep, works as a potential treatment for patients with non-infectious, intermediate, posterior- or pan-uveitis. Izokibep is an experimental drug which is not approved by Health Authorities including the U.S. Food and Drug Administration (FDA) for the treatment of non-infectious, intermediate-, posterior- or pan-uveitis and its use in this research study is investigational. The study drug, Izokibep is a compound that acts by binding to interleukin 17A (IL-17A), which is a type of protein present in the human body that is responsible for inflammation. Izokibep acts by blocking (inhibiting) inflammation from IL-17A. Approximately 100 people will take part in this study at several different locations in the United States and Europe.

Lumina: Inflammatory eye disease

A Phase III, Multicenter, Sham-Controlled, Randomized, Double-Masked Study Assessing the Efficacy and Safety of Intravitreal Injections of 440 ug DE-109 for the Treatment of Active, Non Infectious Uveitis of the Posterior Segment of the Eye.

ADalimumab Versus conventional ImmunoSupprEssion for uveitis (ADVISE) Trial

The ADVISE Trial is a randomized, parallel-treatment, comparative effectiveness trial, comparing adalimumab to conventional (small molecule) immunosuppression for the treatment of non-infectious, intermediate, posterior, and panuveitides. The ADVISE Trial Research Group Funded by the National Eye Institute, the National Institutes of Health.